Latest Conference Articles

Clemens A. Schmitt, MD, director and professor at Berlin School of Integrative Oncology, discusses a conceptually novel treatment approach to classical Hodgkin lymphoma.

Neil L. Berinstein, MD, professor, University of Toronto, Sunnybrook Health Sciences Centre, discusses combination treatments for patients with high-risk or recurrent follicular lymphoma.

Loretta J. Nastoupil, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses high response rates with prembrolizumab (Keytruda) in combination with rituximab (Rituxan) in patients with relapsed follicular lymphoma.

Sattva Neelapu, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, discusses the ZUMA-1 trial investigating axicabtagene ciloleucel (axi-cel; KTE-C19) for patients with refractory aggressive non-Hodgkin lymphoma.

Brad S. Kahl, MD, professor, Department of Medicine, Oncology Division, Washington University School of Medicine, discusses ADCT-402 for patients with relapsed/refractory B-cell lineage non-Hodgkin lymphoma.

Constantine S. Tam, MD, associate professor, Peter MacCullum Cancer Centre, discusses the phase II and phase III studies investigating the combination of ibrutinib (Imbruvica) plus venetoclax (Venclexta) for patients with mantle cell lymphoma (MCL).

Paolo A. Ascierto, MD, director at the Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, National Tumor Institute Fondazione G. Pascale, discusses findings from a phase Ib/II dose-escalation study evaluating the triple combination therapy with encorafenib, binimetinib, and ribociclib (Kisqali) in patients with BRAF V600-mutant solid tumors and melanoma.

Marina Chiara Garassino, MD, medical consultant in the Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses a subset analysis of the AURA3 trial, which demonstrated significant clinical activity with osimertinib (Tagrisso) for patients with EGFR T790M-mutation positive non–small cell lung cancer (NSCLC) who also harbor brain metastases.

H. Jack West, MD, a thoracic oncologist of Swedish Cancer Institute at Swedish Medical Center, discusses some potential emerging changes coming to the field of EGFR-mutant non–small cell lung cancer (NSCLC), including next-generation EGFR inhibitors such as osimertinib (Tagrisso) that is now being explored in the FLAURA trial as a frontline treatment for these patients.

Ali McBride, PharmD, MS, BCPS, clinical coordinator, Hematology/Oncology, secretary, Association of Community Cancer Centers (ACCC), discusses the importance with and excitement of oral oncolytics.

Gunter von Minckwitz, MD, PhD, president of the German Breast Group in Neu-Isenburg, Germany, discusses the phase III results of the APHINITY trial, which explored the addition of pertuzumab (Perjeta) to standard postoperative trastuzumab (Herceptin) therapy for patients with HER2-positive early breast cancer.

Alice T. Shaw, MD, PhD, associate professor of medicine, Harvard Medical School, attending physician, Thoracic Cancer Program, Massachusetts General Hospital, discusses the phase III results of the international ALEX trial, which compared the alectinib (Alecensa) with crizotinib (Xalkori) in the frontline setting for patients with ALK-positive, metastatic non–small cell lung cancer (NSCLC).

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses the results of a phase II trial exploring the efficacy of abemaciclib as a treatment of brain metastases that are secondary in patients with hormone receptor (HR)-positive,HER2-negative breast cancer.

Jeff Sharman, MD, medical director, Hematology Research, The US Oncology Network, discusses the phase III findings of the GENUINE study, the combination of ublituximab (TG-1101) and ibrutinib (Imbruvica) for patients with previously treated high-risk chronic lymphocytic leukemia (CLL).

Mark S. Soberman, MD, MBA, FACS, was elected as the 2017-2018 President of the Association of Community Cancer Centers (ACCC) discusses his vision for the next generation of multidisciplinary care in an interview during the 2017 ASCO Annual Meeting.

Andrea B. Apolo, MD, principal investigator and the head of the Bladder Cancer Section in the Genitourinary Malignancies Branch at the National Cancer Institute’s Center for Cancer Research, discusses the updated findings of the phase Ib JAVELIN trial exploring avelumab (Bavencio) for the treatment of patients with metastatic urothelial carcinoma.

Deanna J. Attai, MD, assistant clinical professor of surgery at the David Geffen School of Medicine at the University of California Los Angeles (UCLA), breast surgeon at UCLA Health, discusses studies exploring the challenges with survivorship care plan implementation for patients with cancer in an interview during the 2017 ASCO Annual Meeting.

Wafik S. El-Deiry, MD, PhD, FACP, deputy cancer center director, Translational Research Program, co-leader, Molecular Therapeutics Program, professor, Department Hematology/Oncology, William Wikoff Smith Chair in Cancer Research, American Cancer Society Research Professor, discusses the importance of understanding tumor heterogeneity an interview during the 2017 ASCO Annual Meeting.

Arjun V. Balar, MD, assistant professor of medicine, Division of Hematology and Oncology, New York University Cancer Institute, NYU Langone Medical Center, discusses the mature clinical trial results and biomarker findings of KEYNOTE-052, first-line pembrolizumab (Keytruda) in patients with cisplatin-ineligible advanced urothelial cancer, during the 2017 ASCO Annual Meeting.

Sarah Rutherford, MD, John P. Leonard, M.D./Gwirtzman Family Research Scholar in Lymphoma , assistant professor of medicine, Joan and Sanford I. Weill Department of Medicine , Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the classification and prevalence of double-hit and double-expressor lymphomas.

Lisa Giulino Roth, MD, assistant professor of Pediatrics in Medicine, Joan and Sanford I. Weill Department of Medicine , Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses treating adolescent and young adult patients with Hodgkin lymphoma.

Jia Ruan, MD, PhD, associate professor of Clinical Medicine, Division of Hematology and Medical Oncology at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the classification of T-cell lymphomas.

Tsiporah B. Shore, MD, associate director of the Blood and Bone Marrow Transplant Program of Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses stem cell transplantation in patients with hematologic malignancies and are of ethnic populations.

Sanjiv S. Agarwala, MD, chief of medical oncology and hematology, St. Luke’s Cancer Center, professor of Medicine, Temple University School of Medicine, discusses whether the overall survival (OS) justifies the toxicities demonstrated in the CheckMate-067 trial for patients with melanoma.

Nadine Abi-Jaoudeh, MD, associate professor, Department of Radiological Sciences, director, Research of Interventional Radiology in the Department of Radiological Sciences, University of California Irvine School of Medicine, discusses the combination of tirapazamine (SR-4233) and transarterial embolization in hepatocellular carcinoma (HCC).

Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer (BCLC) at University of Barcelona, discusses the recent success of regorafenib (Stivarga) in hepatocellular carcinoma (HCC) and its impact on the field.

David James Pinato, MD, MRCP, PhD, Faculty of Medicine, Department of Surgery and Cancer, NIHR Academic Clinical Lecturer, Imperial College London, discusses a study of intratumor heterogeneity in the regulation of immune-tolerogenic pathways in primary and metastatic hepatocellular carcinoma.

Tomi Jun, MD, Stanford University School of Medicine, discusses the results of a study of cirrhosis and long-term survival in patients with cryptogenic hepatocellular carcinoma.

Nadine Abi-Jaoudeh, MD, associate professor, Department of Radiological Sciences, director, Research of Interventional Radiology in the Department of Radiological Sciences, University of California Irvine School of Medicine, discusses the potential for immunotherapy in advanced hepatocellular carcinoma.

Amira Abdelhamid, assistant lecturer, German University in Cairo, discusses microRNA-34a and natural killer (NK) cells in hepatocellular carcinoma (HCC).